Latest Multiple myeloma Stories
CALGARY, April 7, 2014 /PRNewswire/ - Oncolytics Biotech Inc.
GRAPEVINE, Texas, Feb.
Phase 1 Trial of BL-8040 expected to begin in Q2 2014; top-line results expected in H2 2014 JERUSALEM, Jan.
Adding bortezomib (Velcade) to standard preventive therapy for graft-versus-host-disease (GVHD) results in improved outcomes for patients receiving stem-cell transplants from mismatched and unrelated donors.
“Dual Inhibition Of Mcl-1 By The Combination Of Carfilzomib and TG02 In Multiple Myeloma” and “Leukemia Stem/Progenitor Cells From AML Patients Treated With The Multi-Kinase Inhibitor TG02
TG02 synergizes with carfilzomib in multiple myeloma models; data to be presented at ASH 2013 Annual Meeting. San Diego (PRWEB) December 03, 2013 Tragara
- A morbid dread of being buried alive. Also spelled 'taphiphobia'.